MDM2 and sarcoma: To summarize, studies varying from case reports to nationwide registries of cardiac sarcoma patients represent ongoing work in finding the best strategy to classify and describe these tumours based on genomic profiles, histological traits, immune phenotypes, and molecular characterization; the core role in addressing primary intimal sarcomas being played by MDM2 status [85,86,87,88,89,90].